Welcome to our dedicated page for Cryo-Cell Intl news (Ticker: CCEL), a resource for investors and traders seeking the latest updates and insights on Cryo-Cell Intl stock.
About Cryo-Cell International Inc. (CCEL)
Cryo-Cell International Inc., founded in 1989, is a pioneering company in the biotechnology and healthcare sectors, specializing in cellular processing and cryogenic storage. As the first cord blood bank to separate and store stem cells in 1992, Cryo-Cell has established itself as a leader in the field of regenerative medicine. The company’s mission revolves around providing families and public health organizations with cutting-edge solutions for the collection, processing, and preservation of stem cells derived from umbilical cord blood, cord tissue, and menstrual stem cells. With a global client base exceeding 270,000, Cryo-Cell is a trusted name in stem cell banking, known for its unwavering commitment to quality and innovation.
Core Business Areas
- Private Family Cord Blood Banking: Cryo-Cell offers families the opportunity to preserve stem cells from umbilical cord blood and tissue for potential future medical use. These stem cells are stored in the company’s state-of-the-art cryogenic facilities, ensuring long-term viability and accessibility.
- Public Cord Blood Banking: The company also engages in public cord blood banking, facilitating the collection and storage of stem cells for broader medical and research applications. This segment supports advancements in regenerative medicine and provides critical resources for public health initiatives.
- PrepaCyte CB Technology: Cryo-Cell manufactures and markets PrepaCyte CB, a proprietary processing technology designed to enhance the efficiency and quality of umbilical cord blood stem cell processing. This technology underscores the company’s commitment to innovation and excellence in cellular processing.
Competitive Positioning
Cryo-Cell’s competitive edge lies in its vertically integrated operations, which allow the company to maintain complete control over every step of the processing, testing, and cryopreservation process. This ensures the highest quality standards and reliability for its clients. Additionally, the company’s long-standing history and track record of 100% specimen viability upon thaw set it apart from competitors in the cord blood banking industry. By combining advanced technology with decades of experience, Cryo-Cell has positioned itself as a trusted partner in the evolving field of regenerative medicine.
Industry Context and Market Relevance
The stem cell banking industry is a vital component of the broader biotechnology and healthcare sectors, driven by advancements in regenerative medicine and personalized therapies. Cryo-Cell operates at the intersection of these trends, offering services that address the growing demand for stem cell-based treatments. Its focus on both private and public banking diversifies its revenue streams and enhances its relevance in multiple market segments. As awareness of the potential applications of stem cells continues to grow, Cryo-Cell is well-positioned to capitalize on these opportunities while navigating challenges such as regulatory compliance and competitive pressures.
Commitment to Quality and Innovation
Cryo-Cell’s dedication to quality is evident in its state-of-the-art facilities and rigorous processes. The company’s ability to ensure 100% viability of specimens upon thaw highlights its expertise and reliability. Furthermore, its investment in proprietary technologies like PrepaCyte CB demonstrates a commitment to staying at the forefront of innovation in cellular processing. These factors contribute to Cryo-Cell’s reputation as a leader in the stem cell banking industry.
Conclusion
In summary, Cryo-Cell International Inc. is a trailblazer in the field of cellular processing and cryogenic storage, offering comprehensive solutions for stem cell preservation. With a strong emphasis on quality, innovation, and customer trust, the company plays a pivotal role in advancing regenerative medicine and personalized healthcare. Its dual focus on private and public banking, coupled with its proprietary technologies, positions it as a key player in the biotechnology landscape.
Cryo-Cell International, Inc. (CCEL) announced its fiscal first-quarter results for the period ending February 28, 2023. The company reported revenues of
Net income for the quarter was approximately
Cryo-Cell International (CCEL) reported fiscal 2022 results with consolidated revenues of $30.3 million, up from $28.9 million in fiscal 2021. Processing and storage fees led revenue at $29.8 million. Net income grew to $2.8 million or $0.33 per share, compared to $2.1 million or $0.26 per share in 2021. Key factors included a 5% increase in revenue and a 2% decrease in the cost of sales. The company continues to expand services, including a partnership with Duke University and the launch of ExtraVault, enhancing its biostorage capabilities.
Cryo-Cell International (CCEL) reported a 3% revenue increase in Q3 2022, reaching $7.7 million, compared to $7.5 million in Q3 2021. Processing and storage fees accounted for the majority at $7.5 million. However, net income decreased to $467,000 ($0.06 per share) from $857,000 ($0.10 per share) year-over-year. Cost of sales fell by 4%, while SG&A expenses rose by 3%. The company highlights its partnerships and advanced processing technologies as core strengths.
Cryo-Cell International, Inc. (CCEL) has announced a special cash dividend of $0.90 per share for shareholders of record as of September 2, 2022. The decision reflects the Board's commitment to reward long-term investors while advancing its cellular therapies using cord blood and tissue. Founded in 1989, Cryo-Cell is renowned as the first private cord blood bank and has handled over 500,000 samples globally. The company also engages in clinical applications and has partnered with Duke University for public banking.
Cryo-Cell International, Inc. (CCEL) will transition its stock listing from the Nasdaq Capital Market to the NYSE American on August 30, 2022. Chairman David Portnoy believes this move will enhance trading liquidity for shareholders. The last trading date on Nasdaq is expected to be August 29, 2022. Founded in 1989, Cryo-Cell is renowned for being the first private cord blood bank, with over 500,000 parents utilizing its services globally. The company holds numerous accreditations and a partnership with Duke University, emphasizing its commitment to advanced cellular therapies.
Cryo-Cell International, Inc. (CCEL) reported a revenue increase of 6% in Q2 fiscal 2022, reaching $7.63 million compared to $7.21 million in Q2 fiscal 2021. Processing and storage fees accounted for $7.48 million. However, net income fell to $634,719 ($0.08 per basic share) from $1.17 million ($0.15 per basic share) year-over-year, driven by a 24% rise in selling, general, and administrative expenses. The company continues to enhance its services and expand its operations, including the launch of ExtraVault for biostorage.
Cryo-Cell International, Inc. (CCEL) reported financial results for the first quarter of fiscal 2022, ending February 28. Revenue increased to $7.26 million, up from $6.86 million year-over-year. Processing and storage fees accounted for $7.12 million of this total. Net income rose to approximately $832,000 or $0.10 per share, compared to $694,000 in the previous year. The company continues to focus on expanding its cellular therapy initiatives while managing costs effectively, despite a slight decrease in public banking revenue.
Cryo-Cell International (CCEL) has signed a purchase contract for a new 56,000 sq ft facility in the Research Triangle, NC, to enhance its cryopreservation services. This facility will support the launch of ExtraVault, aimed at providing biorepository services to biopharmaceutical companies. The company has over 30 years of experience in biological specimen handling and plans to implement a robust inventory management system. Cryo-Cell’s mission focuses on premier cryopreservation and cellular therapies, with a strong commitment to quality and innovation in the healthcare sector.
Cryo-Cell International, Inc. (CCEL) has issued its 2021 Annual Letter to shareholders, highlighting a cash flow of $7.9 million and a revenue decline to $28.9 million, down from $31.1 million in 2020. The net income also decreased to $2.1 million. Factors affecting performance included a drop in U.S. birth rates due to Covid-19, industry price pressures, and loss of a significant licensing agreement in India. Looking forward, the company plans to open a cellular therapy institute and has proposed the acquisition of a facility in Durham, NC for various operational expansions.
Cryo-Cell International (CCEL) reported fiscal 2021 results, revealing a decline in revenues to $28.9 million, down from $31.1 million in 2020. Processing and storage fees accounted for $28.4 million, while net income fell to $2.1 million ($0.26 per basic share), down from $3.6 million in the previous year. The company faced a 7% revenue drop and increased operational expenses. Notably, an impairment charge of $1.2 million was recorded due to changes in inventory recovery estimates. While the company continues its legacy as a leading cord blood bank, these results may raise concerns among investors.
FAQ
What is the current stock price of Cryo-Cell Intl (CCEL)?
What is the market cap of Cryo-Cell Intl (CCEL)?
What does Cryo-Cell International Inc. do?
What is Cryo-Cell’s competitive advantage?
How does Cryo-Cell generate revenue?
What industries does Cryo-Cell operate in?
What is PrepaCyte CB?
Who are Cryo-Cell’s primary customers?
What makes Cryo-Cell unique in the stem cell banking industry?
How does Cryo-Cell support public health initiatives?
What role does Cryo-Cell play in regenerative medicine?
Where are Cryo-Cell’s facilities located?
